GlassScriptPhysician profile
Emel Sule Yalcin
NPI 1457024176
$3,029.59
in general payments reported to CMS, 2019-2025
7 companies · $2,365 in 2025
The $2,365 reported for 2025 was more than what 84% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $280 · 2024: $385 · 2025: $2,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358 · Education: $1,000 · Travel and Lodging: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.75 |
| Education | $1,000.00 |
| Travel and Lodging | $671.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,700.82 | 2025 | |
| Davol INC. | $469.69 | 2024-2025 | Phasix Mesh |
| Integra Lifesciences Corporation | $343.21 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Tela Bio, INC. | $168.41 | 2024 | Ovitex 2s |
| W. L. Gore & Associates, INC. | $122.59 | 2023-2024 | Gore Viabahn Vbx Balloon Expandable Endo, Gore Viabahn Endoprosthesis |
| Acera Surgical, INC. | $119.01 | 2023 | Restrata Wound Matrix |
| Avita Medical Americas, LLC | $105.86 | 2025 | Cohealyx, Permeaderm, Recell |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emel Yalcin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.